In IPF, nintedanib plus pirfenidone combined therapy is associated with a smaller FVC decline than monotherapy.

Published Date: 03 Nov 2023

The combination of nintedanib and pirfenidone is well tolerated and associated with a lower decline in FVC in IPF patients when compared to monotherapy, according to a recent study published in the.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Stem Cell Selection Unneeded for SSc Transplant Therapy?

2.

Lung Transplant for Lung Cancer: Promising, in Rare Cases

3.

Rural-urban disparities seen in cervical cancer

4.

Obesity linked to subsequent neoplasms in childhood cancer survivors

5.

New policy review highlights the importance of health-related quality of life in advanced cancer


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot